A patient harboring an ANO10-RAF1 fusion displayed sensitivity to trametinib [8], and another melanoma harboring a GOLGA4-RAF1 fusion was associated with increased ERK activation and significant response to MEK inhibitor treatment [7]. Here, RAF1 is linked to melanoma.